Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study of a Generic Enoxaparin Sodium to Clexane® After Single Subcutaneous Dose in Healthy Human Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:- Volunteers must fulfill all of the following inclusion criteria to be eligible for participation in the study, unless otherwise specified.~1. Age: 18 to 45 years old, both inclusive.~2. Gender: Male and/or non-pregnant, non-lactating female.~   A. Female of childbearing potential must have a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test performed within 28 days prior to first dosing day. They must be using an acceptable form of contraception.~   B. For female of childbearing potential, acceptable forms of contraception include the following:~   i. Non hormonal intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or~   ii. Barrier methods containing or used in conjunction with a spermicidal agent, or~   iii. Surgical sterilization or~   iv. Practicing sexual abstinence throughout the course of the study.~   C. Female will not be considered of childbearing potential if one of the following is reported and documented on the medical history:~   i. Postmenopausal with spontaneous amenorrhea for at least one year, or~   ii. Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or~   iii. Total hysterectomy and an absence of bleeding for at least 3 months.~3. BMI: 18.5 to 30.0 kg/m2, both inclusive; BMI value should be rounded off to one significant digit after decimal point (e.g. 30.04 rounds down to 30.0, while 18.45 rounds up to 18.5).~4. Volunteer with at least 50 kg weight~5. Able to read \& understand informed consent document and give written informed consent to participate in the study~6. Non-smokers and non-tobacco users (i.e. having no past history of smoking and tobacco consuming for at least one year prior to study)~7. Non-alcoholic users will be eligible to participate in this study (i.e. having no past history of drinking alcohol for at least one year prior to study).~8. Able to communicate effectively with study personnel.~9. Willing to provide written informed consent to participate in the study.~10. All volunteers must be judged by the principal or sub-investigator or physician as normal and healthy during a pre-study safety assessment performed within 28 days of the first dose of study medication which will include:~    1. A physical examination (clinical examination) with no clinically significant finding.~   2. Results within normal limits or clinically non-significant for the following tests: haematology, biochemistry, serology, coagulogram and urinalysis~Exclusion Criteria:-~Volunteers must not be enrolled in the study if they meet any one of the following criteria:~1. History of hypersensitivity or idiosyncratic reaction to Enoxaparin Sodium, pork, heparin or its derivatives, other low molecular weight heparins or other related drugs, or any of its formulation ingredients.~2. Have significant diseases or clinically significant abnormal findings during screening \[medical history, physical examination (clinical examination), laboratory evaluations, ECG, chest X-ray recording, obstetrics and gynecological history and examination (for female volunteers)\].~3. Any disease or condition like diabetes, psychosis or others, which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system or any other body system.~4. History or presence of bronchial asthma.~5. Use of any hormone replacement therapy within 3 months prior to the first dose of study medication.~6. A depot injection or implant of any drug within 3 months prior to the first dose of study medication.~7. Use of CYP enzyme inhibitors or inducers within 30 days prior to the first dose of study medication (see http://medicine.iupui.edu/clinpharm/ddis/main-table).~8. History or evidence of drug dependence.~9. History of difficulty with donating blood or difficulty in accessibility of veins.~10. A positive hepatitis screen (includes subtypes B \& C).~11. A positive test result for HIV antibody and / or syphilis (RPR).~12. Volunteers who have received a known investigational or equivalent to this drug within seven elimination half-life of the administered drug prior to the first dose of study medication.~13. Volunteers who have donated blood or loss of blood 50 ml to 100 ml within 30 days or 101 ml to 200 ml within 60 days or \>200 ml within 90 days (excluding volume drawn at screening for this study) prior to first dose of study medication, whichever is greater.~14. Intolerance to venipuncture~15. Any food allergy, intolerance, restriction or special diet that, in the opinion of the principal investigator or sub-investigator, could contraindicate the volunteer's participation in this study.~16. Institutionalized volunteers.~17. Use of any prescribed medications within 14 days prior to the first dose of study medication.~18. Use of any OTC products, vitamin and herbal products, etc., within 7 days prior to the first dose of study medication.~19. Use of grapefruit and grapefruit containing products within 7 days prior to the first dose of study medication.~20. Ingestion of any caffeine or xanthine products (i.e. coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.), recreational drugs within 48 hours prior to the first dose of study medication.~21. Ingestion of any unusual diet, for whatever reason (e.g.: low sodium) for three weeks prior to the first dose of study medication.~22. History or presence of active major bleeding.~23. History or presence of Thrombocytopenia.~24. Volunteer having Platelet count lower than lower limit of normal range during screening.~25. Volunteer having Prothrombin Time and Activated Partial Thromboplastin Time 1.1 times higher than the upper limit of normal range during screening.~26. Volunteer having INR outside of normal range during screening.~27. Presence of minor bleeding episodes such as epistaxis, rectal bleeding and gingival bleeding.~28. Volunteers with history of stomach ulcer/duodenal ulcer/intestinal ulcers.~29. Volunteers have undergone any surgery in recent past.~30. Volunteers with the history of piles and fissure.~31. Volunteer having any tattoo or any other type of scar at site of injection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 - AB treatment sequence (Type: EXPERIMENTAL): Period 1 - Test Product (A): Enoxaparin Sodium pre-filled syringe BP 40 mg/0.4 ml of Venus Remedies Limited, India.~Period 2 - Reference Product (B): 'Clexane®' (Enoxaparin Sodium pre-filled syringe; 40 mg/0.4 ml) of Sanofi, Germany.
- Cohort 2 - BA treatment sequence (Type: EXPERIMENTAL): Period 1 - Reference Product (B): 'Clexane®' (Enoxaparin Sodium pre-filled syringe; 40 mg/0.4 ml) of Sanofi, Germany.~Period 2 - Test Product (A): Enoxaparin Sodium pre-filled syringe BP 40 mg/0.4 ml of Venus Remedies Limited, India.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete